Jason Mouabbi
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jason Mouabbi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 20:01 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07229417 · A Trial Evaluating the Efficacy of Ivonescimab in Metastatic Endocrine Refractory HR-positive HER2-negative or Triple Negative Invasive Lobular CarcinomaM.D. Anderson Cancer Center · recruiting · Metastatic Endocrine Refractory, Triple Negative Invasive Lobular Carcinoma · principal investigator
- Ph2NCT06408168 · Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)M.D. Anderson Cancer Center · terminated · Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 20:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 20:01 UTC. The ranking covers the 200 most relevant of 1 PubMed records, and a shared surname and initials can bring in a namesake. All 1 on PubMed